4:37 PM ET
8-K
M&A Deal
PTC Therapeutics M&A Deal with Sangamo Therapeutics, Inc.
PTC Therapeutics has completed its acquisition of ST-920 (isaralgagene civaparvovec), a BLA-stage AAV gene therapy for Fabry disease, from Sangamo Therapeutics. The company expects to complete a rolling Biologics License Application (BLA) submission to the FDA for accelerated approval in the fourth quarter of 2026. The acquisition adds a potential one-time treatment for Fabry disease to PTC's rare disorder pipeline.
- Counterparty
- Sangamo Therapeutics, Inc.